Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock.

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best quality stocks to invest in now.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day,

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.